SEC Tracker
Get the app

Cytokinetics CYTK

Robert Arthur Harrington (Director) was awarded 195 CYTK at $63.92, worth $12K

Form
4
Filed
Importance
Routine
  1. Robert Arthur Harrington acquired 195 shares on Oct 16, 2026
  2. Shares acquired at $63.92
  3. Harrington now holds 22,127 shares
  4. Transaction was part of director equity program

Written from the Form 4 on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Cytokinetics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. TG Therapeutics TGTX public float $2.5B, Jun 30, 2025
  2. Catalyst Pharmaceuticals CPRX public float $2.5B, Jun 30, 2025
  3. Summit Therapeutics SMMT public float $2.5B, Jun 30, 2025
  4. Xenon Pharmaceuticals XENE public float $2.4B, Jun 30, 2025
  5. Carisma Therapeutics CARM

Data on this page was fetched . The filing on SEC.gov is the record.